AB175. Girdin protein is a novel prognosis predictor for patients with non-muscle invasive bladder cancer

Objective: This study aimed to determine the expression status of actin-binding protein Girdin in non-muscle invasive bladder cancer (NMIBC) tissues, and to explore the relationships between Girdin expression and the clinicopathological characteristics of bladder carcinoma.

Methods: This study included 160 patients with NMIBC who underwent surgery from January 2006 to January 2011 at Second Hospital of Tianjin Medical University. The correlations between Girdin expression and the clinicopathological parameters were examined by Chi-square test. Recurrence-free survival (RFS) and progression-free survival (PFS) were analyzed using Kaplan-Meier method. The prognostic significance of Girdin expression was assessed using univariate and multivariate Cox regression analysis models.

Results: Girdin positivity was more frequently seen in high-grade tumors than in low-grade tumors (P=0.019), and in undifferentiated tumors than in differentiated tumors (P=0.028). In Kaplan-Meier analysis, expression of Girdin was significantly associated with lower RFS (P=0.007) and PFS (P=0.024) rates. The univariate analysis revealed that Girdin expression was a risk factor for both recurrence and progression of NMIBC. Further multivariate analysis identified Girdin as an independent predictor of tumor recurrence [hazard ratio (HR) 2.056, 95% CI, 1.213–3.483, P=0.007].

Conclusions: The present study suggests that Girdin is differentially expressed in bladder tumors and may represent an independent predictor of prognosis for patients with NMIBC.

Keywords: Girdin; bladder cancer; non-muscle invasive bladder cancer (NMIBC); recurrence and progression